Clinical Trial Update: Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating trastuzumab deruxtecan as first-line therapy for HER2-positive metastatic breast cancer with proactive toxicity mana…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Breast Cancer Stage IV | Phase 2 | Status: RECRUITING